Clinical application of Duvelisib

Duvelisib (Duvelisib) is a new type of leukocyte signaling pathway inhibitor that has been approved for the treatment of specific types of lymphoma and leukemia. Its clinical application mainly covers the following fields:

1. Tcell lymphoma: Tcell lymphoma is a group of rare but malignant lymphomas involving T lymphocytes. Duveliced u200bu200bhas shown certain efficacy in the treatment of adult T cell leukemia lymphoma (ATLL) and lymphoma cell leukemia (CTCL). These diseases often present with skin lesions, swollen lymph nodes and other symptoms, and duveliside has the potential to slow the progression of the disease and improve patient survival rates.

2. SmallB cell lymphoma: This includes multiple subtypes such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Duveliced u200bu200bis approved for the treatment of relapsed smallBcell lymphoma, including some refractory and relapsed disease. The application of duvelised can improve disease control and patient survival rates.

3. Maintenance treatment after lymphoma treatment: In some cases, duveliced can also be used as maintenance treatment after lymphoma treatment to extend the progression-free survival of the disease and improve the patient's quality of life.

The original drug of Duvelisel Capsules has been launched in China, but it is not covered by medical insurance. Patients can buy it domestically at a price of more than 20,000 yuan. For specific prices, please consult the local hospital pharmacy.

Overall, duvliside represents a new treatment option, especially for patients who are not candidates for conventional treatments or who have already experienced relapse. It offers hope for these patients by targeting multiple signaling pathways to interfere with the growth and spread of leukemia and lymphoma cells. Patients should use duvelised under the guidance of a doctor and comply with the treatment plan to ensure the best therapeutic effect. The clinical application of duvelicer marks an important advance in the treatment of leukemia and lymphoma.